GU Cancers 2023 | How far away are we from implementing liquid biopsy approaches in GU cancers?

Lucia Nappi, MD, University of British Columbia, Vancouver, Canada, discusses the implementation of liquid biopsy approaches in GU cancer, including with miR-371 in testicular cancer. In bladder cancer, circulating tumor DNA (ctDNA) is under investigation to identify patients with residual disease following radical cystectomy and in prostate cancer there are various gene expression signatures being assessed to predict patient outcomes. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.